Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Turning tumor-promoting fibroblasts against pancreatic cancer

Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer's growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease.

26 Oct 2018

Molecular breakthrough may improve prognosis for pancreatic cancer

Scientists have discovered a method by which fibroblasts in the stroma of pancreatic tumors can be reprogrammed to suppress tumor cell growth.

26 Oct 2018

Influenza virus can evolve resistance to experimental antiviral drug

The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found.

25 Oct 2018

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

A new drug that works against flu has been developed and has been approved by the Food and Drug Administration (FDA) yesterday (24th October 2018). Until now the only drug available for flu is oseltamivir (Tamiflu) which is to be administered by two pills per day for five days after symptoms appear.

25 Oct 2018

Battling against resistant and sensitive types of influenza A

Another flu season is here, which means another chance for viruses to mutate. Already, most influenza A viruses contain a mutation that confers resistance against one class of antiviral medications, and the bugs are steadily gaining resistance against another class.

25 Oct 2018

FDA approves new antiviral flu treatment

Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

24 Oct 2018

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Results from a new study suggest that high-dose influenza vaccine is associated with lower risk for hospitalizations in kidney failure patients on dialysis. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology

24 Oct 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

Research suggests new approach to protect from common cold

As temperatures drop and the sniffles start, take hope; research published this summer suggests a new approach to protect ourselves from the common cold.

24 Oct 2018

Temperature increases in Zambezi Valley may cause major declines in tsetse populations

A new study, based on 27 years of data from Mana Pools National Park in Zimbabwe, suggests that temperature increases over the last three decades have already caused major declines in local populations of tsetse flies.

24 Oct 2018

How to avoid shoulder injury related to vaccine administration

A study by researchers at the University of Waterloo reiterates the need for health care professionals, including pharmacists, to take certain precautions to minimize the risk of their patients suffering shoulder injury related to vaccine administration

24 Oct 2018

Impact of climate change on sleeping sickness vector population in Africa

LSTM's Dr Jennifer Lord is first author on a paper looking at the impact of climate change on the vectors of sleeping sickness in Africa.

23 Oct 2018

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

23 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Turning tumor-promoting fibroblasts against pancreatic cancer

Molecular breakthrough may improve prognosis for pancreatic cancer

Influenza virus can evolve resistance to experimental antiviral drug

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

Battling against resistant and sensitive types of influenza A

FDA approves new antiviral flu treatment

High-dose influenza vaccine associated fewer hospitalizations in dialysis patients

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Research suggests new approach to protect from common cold

Temperature increases in Zambezi Valley may cause major declines in tsetse populations

How to avoid shoulder injury related to vaccine administration

Impact of climate change on sleeping sickness vector population in Africa

Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in